TABLE 1

Subject characteristics

Nondiabetic control subjectsType 1 diabetic subjectsIslet transplant recipients
Age (years)43 ± 246 ± 241 ± 4
Sex (male/female)5/26/04/2
BMI (kg/m2)24.1 ± 1.025.1 ± 1.122.0 ± 1.3
HbA1c (%)5.3 ± 0.17.1 ± 0.7*6.3 ± 0.3
Basal glucose (mg/dl)85 ± 3110 ± 20113 ± 8
Basal insulin (μU/ml)8 ± 120 ± 412 ± 3
Basal C-peptide (ng/ml)0.8 ± 0.10.1 ± 0.00.9 ± 0.3
Basal glucagon (pg/ml)74 ± 1196 ± 1067 ± 6§
Basal PP (pmol/l)23 ± 649 ± 2125 ± 4
Type 1 diabetes duration (years)28 ± 330 ± 4
InsReq (units · kg−1 · day−1)0.60 ± 0.070.11 ± 0.05
Hypoglycemia survey6.7 ± 0.30.8 ± 0.4
IE/kg transplanted**15,075 ± 1,918
  • Data are means ± SE. Basal levels of glucose and islet hormones are the mean of the −30 and 0 min values prior to the start of the hypoglycemic clamp.

  • * P < 0.05 and

  • P < 0.01 for comparison with control subjects.

  • P < 0.01 and

  • § P < 0.05 for comparison with type 1 diabetic subjects.

  • Exogenous insulin requirements at the time of study.

  • Survey of hypoglycemia severity (7, most; 0, none) developed by Clarke et al. (23).

  • ** Islet equivalents (IEs) transplanted per kilogram recipient body weight, where an IE approximates a standard islet diameter of 150 μm. PP, pancreatic polypeptide.